Oral AG-120 for advanced blood cancers with an IDH1 mutation
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your blood cancer is advanced and has an IDH1 R132 mutation confirmed by testing.
- You can provide repeated bone marrow biopsies, blood samples, and urine samples during the study.
- Your body’s performance status is good (ECOG 0–2).
- Your organ bloodwork is acceptable (liver and kidney numbers are within limits, and platelets can be supported with transfusions).
- If you can become pregnant, you have a negative pregnancy test before starting and on the first day of study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
This study tests whether adding a targeted pill (ivosidenib) to another maintenance drug (oral azacitidine) can help keep your leukemia in remission longer. It is for older adults with a specific gene change (IDH1) who have finished intensive chemotherapy.
This trial tests a new drug called HMPL-306 in people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It is for patients whose leukemia cells have a specific change in the IDH1 or IDH2 gene.
This trial tests a combination of two oral drugs (decitabine and ivosidenib) as a first treatment for older or frail adults with AML that has an IDH1 mutation. The goal is to see if this pill-only regimen is safe and effective without needing intensive chemotherapy.
This Phase 1 study tests APG-115 alone or with azacitidine or cytarabine in people whose acute myeloid leukemia (AML) or high-risk MDS has come back or hasn’t responded. The goal is to see safety and whether the treatment can work for these conditions.
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.